Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ASND
Ascendis Pharma A/S
stock NASDAQ

At Close
Jul 30, 2026 3:59:55 PM EDT
251.15USD-0.355%(-0.90)475,231
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-252.05)0
After-hours
Jul 27, 2026 4:00:30 PM EDT
253.42USD+0.022%(+0.05)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
12:02PM EST  Where Ascendis Pharma Stands With Analysts   Benzinga
Jan 13, 2022
11:53AM EST  Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval   Benzinga
11:47AM EST  Ascendis Pharma Reports Received European Approval For TransCon Somatropin For Pediatric Growth Hormone Deficiency   Benzinga
08:00AM EST  Ascendis Pharma A/S Receives European Approval for   GlobeNewswire Inc
Jan 10, 2022
08:00AM EST  Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key milestones at the 40th Annual J.P. Morgan Healthcare Conference. Details of the update are outlined below, and CEO Jan Mikkelsen will give a virtual presentation to attendees from 3:00-3:40 p.m. Eastern Time.   GlobeNewswire Inc
Jan 6, 2022
10:12AM EST  Where Ascendis Pharma Stands With Analysts   Benzinga
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022   Benzinga
08:59AM EST  Cowen & Co. Initiates Coverage On Ascendis Pharma with Market Perform Rating, Announces Price Target of $136   Benzinga
Jan 4, 2022
08:01AM EST  Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Company executives will provide a business overview and update on the companys pipeline programs.   GlobeNewswire Inc
Dec 16, 2021
05:09PM EST  17:08 Thursday, December 16, 2021Wedbush (RTTNews) - Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $191 Price Target   RTTNews
Dec 14, 2021
08:00AM EST  TransCon PTH Phase 3 topline results expected in Q1 2022 and, if positive, planned NDA submission in Q3 2022 followed by expected MAA submission in Q4 2022   GlobeNewswire Inc
Dec 8, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021   Benzinga
07:27AM EST  Wells Fargo Initiates Coverage On Ascendis Pharma with Overweight Rating, Announces Price Target of $176   Benzinga
Dec 7, 2021
05:41PM EST  Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday, December 14, 2021.   GlobeNewswire Inc
Nov 23, 2021
06:00AM EST  Ascendant Resources (the Company) (TSXV:ASND), is pleased to announce that it has commenced its drill program that will be used to support an upcoming Feasibility Study at its Lagoa Salgada VMS project, located in the Iberian Pyrite Belt, Portugal.   GlobeNewswire Inc
Nov 22, 2021
05:00PM EST  Ascendant Resources (the Company) (TSX:ASND), is pleased to announce that David Ball has joined Ascendant Resources as Vice President, Business Development.   GlobeNewswire Inc
Nov 19, 2021
08:20AM EST  The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial   Benzinga
07:40AM EST  Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks   Benzinga
Nov 18, 2021
04:46PM EST  Ascendis Pharma A/S Announces Top-Line Results From Week 84 Of Phase 2 PaTH Forward Trial Demonstrating That TransCon PTH Provided Durable Benefit And Was Well-Tolerated In Adults with Hypoparathyroidism   Benzinga
04:42PM EST  58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.   GlobeNewswire Inc
Nov 17, 2021
04:05PM EST  Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore ISI.   GlobeNewswire Inc
Nov 15, 2021
10:52AM EST  10 Biggest Price Target Changes For Monday   Benzinga
10:46AM EST  SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $190   Benzinga
08:00AM EST  Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Companys previously announced $25 million American Depositary Shares (ADS) Share Repurchase Program. Each ADS represents one ordinary share of Ascendis Pharma A/S. The program was executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations.   GlobeNewswire Inc
Nov 12, 2021
07:51AM EST  Ascendis Pharma Gets Positive CHMP Opinion For TransCon HGH For Pediatric Growth Hormone Deficiency   RTTNews
07:38AM EST  Ascendis Pharma A/S Receives Positive CHMP Opinion For TransCon hGH For Patients With Pediatric Growth Hormone Deficiency   Benzinga
07:23AM EST  TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patientswith growth hormone deficiency.   GlobeNewswire Inc
Nov 11, 2021
12:22PM EST  Analyst Ratings For Ascendis Pharma   Benzinga
07:55AM EST  Credit Suisse Maintains Outperform on Ascendis Pharma, Lowers Price Target to $179   Benzinga
Nov 10, 2021
04:43PM EST  Ascendis Pharma Q3 2021 Revenue 1.1M Vs   Benzinga
04:01PM EST  SKYTROFA (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021.   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 9, 2021
11:41AM EST  Ascendis Pharma To Present New Non-Clinical Data For TransCon TLR7/8 Agonist Oncology Program At SITC 2021 Nov. 10-14   Benzinga
08:00AM EST  - In non-clinical models, a single dose of TransCon TLR7/8 Agonist activated critical innate and adaptive immune mechanisms, providing sustained modulation of tumor microenvironments with low systemic exposure.   GlobeNewswire Inc
Nov 8, 2021
08:00AM EST  Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Companys previously announced $25 million American Depositary Shares (ADS) Share Repurchase Program. Each ADS represents one ordinary share of Ascendis Pharma A/S. The program is executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations.   GlobeNewswire Inc
06:00AM EST  Ascendant Resources Signs Definitive Mining Concession Contract   GlobeNewswire Inc
Nov 3, 2021
08:00AM EDT  Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time (ET) to review its third quarter 2021 financial results and provide a business update.   GlobeNewswire Inc
Oct 25, 2021
05:41PM EDT  Ascendant Resources Inc Files Technical Report for Its Lagoa   GlobeNewswire Inc
Oct 20, 2021
10:14AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021   Benzinga
07:28AM EDT  B of A Securities Downgrades Ascendis Pharma to Neutral, Raises Price Target to $169   Benzinga
Oct 15, 2021
08:04AM EDT  Ascendis Pharma Reports US Commercial Launch Of SKYTROFA For Treatment Of Pediatric Growth Hormone Deficiency   Benzinga
08:00AM EDT  Ascendis Pharma A/S Announces U.S. Commercial Launch of   GlobeNewswire Inc
Oct 3, 2021
02:21PM EDT  The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More   Benzinga
Sep 30, 2021
04:03PM EDT  Ascendis Pharma A/S Announces Presentations For TransCon PTH And TransCon CNP At American Society For Bone & Mineral Research 2021 Annual Meeting   Benzinga
04:01PM EDT  Late-breaking oral presentation will feature a comprehensive review of 58-week resultsfrom the companys Phase 2 PaTH Forward Trial   GlobeNewswire Inc
Sep 29, 2021
04:01PM EDT  Ascendis Pharma A/S Announces $25M Buyback   Benzinga
04:01PM EDT  Ascendis Pharma A/S Announces Share Repurchase Program   GlobeNewswire Inc
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 22, 2021
04:29PM EDT  Ascendis Pharma Highlights Mean Bone MIneral Density Data From Phase 2 PaTH Forward Trial Showing Continued Normalization, Stabilization Of BMD Z-scores Between 26-58 Weeks   Benzinga
04:27PM EDT  Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported   GlobeNewswire Inc
Sep 13, 2021
06:00AM EDT  Ascendant Resources Announces After Tax NPV of $246 Million With   GlobeNewswire Inc
Sep 9, 2021
05:09PM EDT  -- Continued improvement in metal Recoveries -- Test work supports at least benchmark IPB recoveries in both Massive Sulphide and Stockwork Ores   GlobeNewswire Inc
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 7, 2021
05:10PM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients lives, today announced that the company will participate in two upcoming investor conferences. Company executives will provide a business overview and update on the companys programs.   GlobeNewswire Inc
05:00PM EDT  TransCon IL-2 /is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation of IL-2R/with low Cmax   GlobeNewswire Inc
Sep 1, 2021
09:01PM EDT  Ascendis Pharma Prices Underwritten Public Offering Of 2.50 Mln ADSs At $160.00/ADS   RTTNews
07:44PM EDT  Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs   GlobeNewswire Inc
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
04:01PM EDT  Ascendis Pharma A/S Announces $400M Proposed Public Offering of ADSs   Benzinga
04:01PM EDT  Ascendis Pharma A/S Announces Proposed Public Offering of ADSs   GlobeNewswire Inc
Aug 29, 2021
09:48AM EDT  The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week   Benzinga
Aug 26, 2021
02:48PM EDT  Mid-Afternoon Market Update: Pure Storage Rises Following Strong Q2 Results; SelectQuote Shares Plunge   Benzinga
12:32PM EDT  What 8 Analyst Ratings Have To Say About Ascendis Pharma   Benzinga
12:13PM EDT  Mid-Day Market Update: Dow Tumbles Over 100 Points; Ascendis Pharma Shares Spike Higher   Benzinga
10:19AM EDT  Mid-Morning Market Update: Markets Mixed; Dollar General Profit Beats Views   Benzinga
10:03AM EDT  Recap: Ascendis Pharma Q2 Earnings   Benzinga
09:49AM EDT  Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $204   Benzinga
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
07:01AM EDT  Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $185   Benzinga
04:56AM EDT  SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $182   Benzinga
01:52AM EDT  Ascendis Pharma A/S (ASND) reported that its second-quarter net loss widened from last year. In addition, the company said that the U.S. Food and Drug Administration approved its Skytrofa for the treatment of Pediatric Growth Hormone Deficiency.   RTTNews
Aug 25, 2021
04:17PM EDT  Ascendis Pharma (2.50) Vs   Benzinga
04:12PM EDT  Announced U.S. Food and Drug Administration Approval of SKYTROFA (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency   GlobeNewswire Inc
03:25PM EDT  Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency   Benzinga
03:25PM EDT  - SKYTROFA, the first FDA approved treatment utilizing TransCon technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies   GlobeNewswire Inc
11:57AM EDT  Ascendis Pharma Shares Halted On Code News Pending   Benzinga
07:30AM EDT  The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug   Benzinga
04:03AM EDT  Earnings Scheduled For August 25, 2021   Benzinga
Aug 17, 2021
04:17PM EDT  Ascendis Pharma A/S Announces Second Quarter 2021 Financial   GlobeNewswire Inc
Aug 6, 2021
07:05AM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced that the company will participate in two upcoming investor conferences in August. Company executives will provide a business overview and update on the companys pipeline programs.   GlobeNewswire Inc
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 21, 2021
02:43PM EDT  Expert Ratings For Ascendis Pharma   Benzinga
06:55AM EDT  SVB Leerink Maintains Outperform on Ascendis Pharma, Lowers Price Target to $178   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 8, 2021
08:02AM EDT  Argus Research Initiates Equity Report Coverage on Ascendant Resources Inc.   PR Newswire
Jul 6, 2021
08:21AM EDT  Ascendis Pharma Says Target Enrollment Achieved In Phase 3 PaTHway Trial Of TransCon   Benzinga
08:00AM EDT  Ascendis expects to complete enrollment of subjects still in screening within one week   GlobeNewswire Inc
Jun 14, 2021
10:02AM EDT  Wedbush Maintains Outperform on Ascendis Pharma, Lowers Price Target to $189   Benzinga
09:50AM EDT  SVB Leerink Maintains Outperform on Ascendis Pharma, Lowers Price Target to $181   Benzinga
09:01AM EDT  Ascendis Pharma On Friday Announced Extension Of FDA Review Period For TransCon hGH (Lonapegsomatropin) For Pediatric Growth Hormone Deficiency   Benzinga
07:52AM EDT  Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $197   Benzinga
07:23AM EDT  Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months   Benzinga
Jun 11, 2021
05:58PM EDT  Ascendis Pharma A/S Announces Extension of U.S. Food and Drug   GlobeNewswire Inc
Jun 3, 2021
02:02PM EDT  Ascendis Pharma's VISEN Says Has Received Investigational New Drug Approval From Center For Drug Evaluation Of National Medical Products Administration For Phase 3 China Clinical Trial Of TransCon PTH Solution For Injection   Benzinga
02:00PM EDT  The first hormone replacement therapy for hypoparathyroidism in China obtains   PR Newswire
Jun 2, 2021
10:38AM EDT  Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates   Benzinga
06:00AM EDT  -- Former Exploration Executive With Significant Experience Developing VMS Deposits Similar to Ascendants Lagoa Salgada Property   GlobeNewswire Inc
Jun 1, 2021
05:31PM EDT  Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates   Benzinga
11:02AM EDT  What 5 Analyst Ratings Have To Say About Ascendis Pharma   Benzinga
08:37AM EDT  Canaccord Genuity Maintains Buy on Ascendis Pharma, Raises Price Target to $196   Benzinga
04:20AM EDT  Earnings Scheduled For June 1, 2021   Benzinga
May 28, 2021
09:22AM EDT  Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $178   Benzinga
07:19AM EDT  Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $201   Benzinga
07:05AM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransContechnologies to create new product candidates that address unmet medical needs, today announcedan online event with members of the hypoparathyroidism community to be held on Tuesday, June 1 in support of World Hypopara Awareness Day.   GlobeNewswire Inc
May 27, 2021
04:02PM EDT  Ascendis Pharma Q1 EPS (1.17) vs (1.32) In Same Qtr. Last Year, Sales 700K vs 2.2M Year Over Year   Benzinga
04:01PM EDT  Pre-launch activities continue in preparation for a potential FDA approval of TransCon hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021   GlobeNewswire Inc
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
06:00AM EDT  -- Appointment of Chief Financial Officer, General Counsel & Corporate Secretary   GlobeNewswire Inc
04:29AM EDT  Earnings Scheduled For May 27, 2021   Benzinga
May 23, 2021
10:06AM EDT  The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation   Benzinga
May 17, 2021
04:05PM EDT  Ascendis Pharma A/S Announces First Quarter 2021 Financial Results   GlobeNewswire Inc
May 12, 2021
04:45PM EDT  Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan   Benzinga
04:28PM EDT  Ascendis Pharma A/S Announces Expansion of Global Clinical Reach   GlobeNewswire Inc
May 11, 2021
08:17AM EDT  Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism   Benzinga
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 10, 2021
05:19PM EDT  Ascendis Pharma A/S Says Preliminary 58-Week Results From Open-Label Extension Of Phase 2 PaTH Forward Trial Of TransCon PTH In Adult Hypoparathyroidism Demonstrated Durable Benefit And Well-Tolerated Safety Profile   Benzinga
05:18PM EDT  58 subjects continue in the open-label extension study for TransCon PTH   GlobeNewswire Inc
May 4, 2021
04:05PM EDT  Ascendis Pharma A/S Announces Participation at the BofA Securities   GlobeNewswire Inc
Apr 21, 2021
04:05PM EDT  Ascendis Pharma A/S Announces Presentations for   GlobeNewswire Inc
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 19, 2021
10:18AM EDT  Stocks That Hit 52-Week Lows On Monday   Benzinga
Mar 31, 2021
11:52AM EDT  Ascendis Pharma Says Co's VISEN's TransCon Human Growth Hormone Phase III Clinical Trial In China Completes Target Patient Recruitment Number As Scheduled   Benzinga
Mar 30, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2021   Benzinga
08:15AM EDT  Oppenheimer Downgrades Ascendis Pharma to Perform   Benzinga
07:05AM EDT  Ascendis Pharma A/S Announces Participation at the J.P. Morgan   GlobeNewswire Inc
Mar 23, 2021
07:11AM EDT  Ascendis Pharma Presents 6-Month Open-Label Extension Data From Phase 2 PaTH Forward Trial Of TransCon PTH At ENDO 2021   RTTNews
07:10AM EDT  Ascendis Pharma A/S Highlights Presentation Of 6-Month Open-Label Extension Data From Phase 2 PaTH Forward Trial Of TransCon PTH In Adult Hypoparathyroidism At ENDO 2021   Benzinga
07:05AM EDT  Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data   GlobeNewswire Inc
Mar 17, 2021
07:30AM EDT  Ascendant Resources Inc. (TSX: ASND) (FRA: 2D9) ("Ascendant" or the "Company) is pleased to announce the beginning of its phase 2 metallurgical test work on both the massive sulphide and stockwork ores at its Lagoa Salgada project in Portugal, following very encouraging results obtained in the first stage of metallurgical test work.   GlobeNewswire Inc
Mar 15, 2021
07:17AM EDT  Ascendis Pharma To Participate At Oppenheimer 31st Annual Healthcare Conference Mar. 17 At 11:20 a.m. ET   Benzinga
07:05AM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, today announced that the company will participate at the Oppenheimer 31st Annual Healthcare Conference. Company executives will provide a business overview and an update on the Companys pipeline programs.   GlobeNewswire Inc
Mar 12, 2021
09:19AM EST  Canaccord Genuity Maintains Buy on Ascendis Pharma, Raises Price Target to $190   Benzinga
Mar 11, 2021
11:25AM EST  Credit Suisse Maintains Outperform on Ascendis Pharma, Lowers Price Target to $176   Benzinga
Mar 10, 2021
04:05PM EST  Ascendis Pharma FY20 Net Loss (8.28) vs (4.69) In FY19, Sales 7M vs 13.4M In FY19   Benzinga
04:01PM EST  Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track   GlobeNewswire Inc
07:26AM EST  The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link   Benzinga
07:05AM EST  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced seven presentations at ENDO 2021, the Endocrine Societys annual meeting, taking place virtually from March 20-23, 2021.   GlobeNewswire Inc
04:04AM EST  Earnings Scheduled For March 10, 2021   Benzinga
Mar 9, 2021
10:16AM EST  Earnings Preview for Ascendis Pharma   Benzinga
Mar 4, 2021
04:05PM EST  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast onWednesday, March 10, 2021at4:30 p.m. Eastern Time(ET) to review its 2020 financial results and provide a business update.   GlobeNewswire Inc
Mar 3, 2021
11:03AM EST  New Mineral Resource Estimate of 4.4Mt Indicated and 7.7Mt Inferred demonstrates significant growth from successful Phase 1 drill program   GlobeNewswire Inc
Feb 26, 2021
07:05AM EST  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the launch of Outgrow GHD, a new online educational resource designed to help caregivers of children with growth hormone deficiency (GHD) in the United States (U.S.) navigate their personal GHD journeys.   GlobeNewswire Inc
Feb 18, 2021
04:05PM EST  Ascendis Pharma A/S Announces Participation at SVB Leerink 10th   GlobeNewswire Inc
Jan 27, 2021
07:30AM EST  -- Following highly successful Phase I program, drilling is expected to continue to significantly expand resources in the south zone   GlobeNewswire Inc
Jan 13, 2021
07:30AM EST  -- 50m Step-out drill holes encounter strong mineralization to expand the wireframe model yet leave the mineralization open to the South and East -- High-grade Copper intersections include 4.20m @ 3.59% CuEq and 10.50m @ 3.61% and Copper Bonanza intervals of 1.00m @ 14.21% CuEq and 1.40m @ 9.86% CuEq.   GlobeNewswire Inc
Jan 10, 2021
07:05PM EST  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, will provide an update on Vision 3x3 and the companys 2021 key milestones at the 39th Annual J.P. Morgan Healthcare Conference.   GlobeNewswire Inc
Jan 8, 2021
10:07PM EST  Development and Commercialization of its Innovative Endocrinology Therapies in Greater China   PR Newswire
09:13PM EST  Ascendis Pharma A/S (ASND) said that it has invested $12.5 million in VISEN Pharmaceuticals, as part of VISEN's $150 million Series B financing.   RTTNews
07:40PM EST  Ascendis Pharma A/S Announces Equity Investment in VISEN   GlobeNewswire Inc
Jan 4, 2021
07:05AM EST  Ascendis Pharma A/S Announces Participation in 39th Annual J.P.   GlobeNewswire Inc
Dec 31, 2020
05:28AM EST  A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Final Trading Session Of 2020   Benzinga
Dec 30, 2020
04:06PM EST  Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon TLR7/8 Agonist Clinical Program   Benzinga
04:05PM EST  - TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response-   GlobeNewswire Inc
Dec 17, 2020
10:17AM EST  Benzinga's Top Upgrades, Downgrades For December 17, 2020   Benzinga
09:57AM EST  Berenberg Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $216   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
04:06PM EST  Ascendis Pharma Reports Chair Michael Wolf Jensen Will Not Stand For Reelection; Names Albert Cha Replacement   Benzinga
04:05PM EST  Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting   GlobeNewswire Inc
Nov 25, 2020
07:05AM EST  Ascendis Pharma A/S Announces Participation at the Evercore ISI   GlobeNewswire Inc
Nov 23, 2020
07:30AM EST  -- Exciting geological phenomena contributes to thesis of significant copper potential beyond existing 2.5MT M&I and 6MT Inferred copper resources in the South Zone   GlobeNewswire Inc
Nov 13, 2020
08:06AM EST  10 Biggest Price Target Changes For Friday   Benzinga
07:36AM EST  Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $199   Benzinga
Nov 12, 2020
08:35AM EST  Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $178   Benzinga
04:57AM EST  SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $191   Benzinga
Nov 11, 2020
05:30PM EST  Event will provide an overview of how Ascendis is applying itsTransCon technology platform and itsunique algorithm for product innovation to the therapeutic area of oncology   GlobeNewswire Inc
04:24PM EST  Recap: Ascendis Pharma Q3 Earnings   Benzinga
04:03PM EST  Ascendis Pharma Q3 Sales 2.76M Up From   Benzinga
04:01PM EST  European Medicines Agency (EMA) validatedthe Marketing Authorisation Application (MAA)for TransConTM hGH (lonapegsomatropin)in pediatric growth hormone deficiency (GHD)   GlobeNewswire Inc
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
04:09AM EST  Earnings Scheduled For November 11, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Nov 5, 2020
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
Nov 3, 2020
07:06AM EST  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it has appointed Mark A. Bach, M.D., Ph.D., as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases.   GlobeNewswire Inc
Nov 2, 2020
04:05PM EST  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast onWednesday, November 11, 2020at4:30 p.m. Eastern Time(ET) to review its third quarter 2020 financial results and provide a business update.   GlobeNewswire Inc
Oct 28, 2020
02:20PM EDT  Ascendis Pharma Option Alert: Dec 18 $165 Calls Sweep (14) near the Ask: 123 @ $7.0 vs 0 OI; Earnings 11/16 After Close [est] Ref=$160.76   Benzinga
Oct 27, 2020
07:30AM EDT  -- Strengthened financial position to advance exploration program at Lagoa Salgada   GlobeNewswire Inc
Oct 23, 2020
08:09AM EDT  Ascendis Pharma A/S Receives Orphan Designation For TransCon PTH For Treatment Of Hypoparathyroidism In Europe   Benzinga
08:05AM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted Orphan Designation to TransCon PTH for the treatment of hypoparathyroidism (HP).   GlobeNewswire Inc
Oct 21, 2020
05:54PM EDT  Ascendis Pharma A/S Announces Presentations For Its Endocrinology Rare Disease Clinical Programs At Upcoming Medical Conference   Benzinga
Oct 13, 2020
08:22AM EDT  Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $194   Benzinga
Sep 28, 2020
07:00PM EDT  - Six-month data from PaTH Forward open-label extension support potential use ofTransCon PTH as a hormone replacement therapy for adult hypoparathyroidism   GlobeNewswire Inc
Sep 23, 2020
04:06PM EDT  Ascendis Pharma A/S Announces Filing Of Clinical Trial Notification For Phase 3 Clinical Trial Of TransCon hGH For Pediatric Growth Hormone Deficiency In Japan   Benzinga
04:05PM EDT  Ascendis Pharma A/S Announces Filing of the Clinical Trial   GlobeNewswire Inc
Sep 15, 2020
05:45PM EDT  Introduces #Together4Growth to increase awareness of childrens growth disorders, including a four-question Growth Quiz to help parents identify signs and symptoms   GlobeNewswire Inc
Sep 11, 2020
02:26PM EDT  Ascendant Resources Inc. (TSX: ASND) ("Ascendant" or the "Company) is pleased to announce the voting results of the Companys 2020 Annual Shareholders Meeting (the Meeting) held earlier today, September 11, 2020 in Toronto, Ontario.   GlobeNewswire Inc
07:05AM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference in September. Company executives will provide a business overview and update on the companys pipeline programs.   GlobeNewswire Inc
Sep 8, 2020
04:45PM EDT  Ascendis Pharma A/S Submits Marketing Authorization Application To European Medicines Agency For TransCon hGH For Treatment Of Pediatric Growth Hormone Deficiency   Benzinga
04:45PM EDT  Ascendis Pharma A/S Submits Marketing Authorisation Application   GlobeNewswire Inc
Sep 4, 2020
08:36AM EDT  Ascendis Pharma: FDA Accepts BLA For TransCon HGH For Pediatric Growth Hormone Deficiency   RTTNews
08:33AM EDT  Ascendis Pharma A/S Announces FDA Accepts Biologics License Application For TransCon hGH For Pediatric Growth Hormone Deficiency   Benzinga
08:30AM EDT  Prescription Drug User Fee Act (PDUFA) target action dateof June 25, 2021   GlobeNewswire Inc
07:05AM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced two presentations for its TransCon PTH program in adult hypoparathyroidism (HP) at the 22nd European Congress of Endocrinology (e-ECE) 2020, taking place online September 59, 2020.   GlobeNewswire Inc
Sep 2, 2020
04:05PM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will participate in the 2020 Wells Fargo Virtual Healthcare Conference in September. Company executives will provide a business overview and update on the companys pipeline programs.   GlobeNewswire Inc
Aug 31, 2020
08:51AM EDT  Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $179   Benzinga
Aug 28, 2020
09:13AM EDT  Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $158   Benzinga
Aug 27, 2020
04:24PM EDT  Ascendis Pharma: Q2 Earnings Insights   Benzinga
04:05PM EDT  Ascendis Pharma Q2 2020 EPS (1.97)   Benzinga
04:01PM EDT  U.S. Biologics License Application for TransCon hGH submitted to U.S. Food and Drug Administration for pediatric growth hormone deficiency   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For August 27, 2020   Benzinga
Aug 13, 2020
04:01PM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast onThursday, August 27, 2020at4:30 p.m. Eastern Time(ET) to review its second quarter 2020 financial results and provide a business update.   GlobeNewswire Inc
Aug 12, 2020
07:13AM EDT  Ascendis Pharma A/S Receives Orphan Designation For TransCon CNP For The Treatment Of Achondroplasia In Europe   Benzinga
07:10AM EDT  Ascendis Pharma: EC Grants Orphan Designation To TransCon C-Type Natriuretic Peptide For Achondroplasia   RTTNews
07:05AM EDT  Ascendis Pharma A/S Receives Orphan Designation for   GlobeNewswire Inc
Aug 4, 2020
08:30AM EDT  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will participate in two upcoming investor conferences in August. Company executives will provide a business overview and update on the companys pipeline programs.   GlobeNewswire Inc
Jul 15, 2020
09:46AM EDT  Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $177   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC